Basilea Pharmaceutica AG BPMUF
84.00 USD 0.00 (+0.00%)
Regular-session close
77.40 Day range 77.40
59.29 52-week range 84.00
- YTD
- +32.81%
- 1 year
- +41.68%
News
seekingalpha.com Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
defenseworld.net Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 474 shares, a growth of…
globenewswire.com Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the…
globenewswire.com Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial…
globenewswire.com Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420 Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor)…
globenewswire.com Basilea announces start of first‑in‑human study of novel antibiotic BAL2420 Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial…
globenewswire.com Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to…
seekingalpha.com Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
globenewswire.com Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance 15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total…
globenewswire.com Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe…
globenewswire.com Basilea provides portfolio update and outlook Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal…
prnewswire.com Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections UNION, N.J., Jan. 7, 2026 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement…
businesswire.com Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI BOSTON--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage…
globenewswire.com Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe…
globenewswire.com Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to…
globenewswire.com Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million
globenewswire.com Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to…
seekingalpha.com Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript Basilea Pharmaceutica AG (OTC:BPMUF) Q2 2025 Earnings Conference Call August 19, 2025 10:00 AM ET Company Participants Adesh Kaul - Chief Financial Officer David Veitch - Chief Executive Officer Marc…
globenewswire.com Basilea on track with strong 2025 half-year results Cresemba ® and Zevtera ® -related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating…
globenewswire.com Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "14-alpha Demethylase Inhibitors - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides…
